Market Overview
The Brazil Genetic Testing Market reached a size of USD 462.1 Million in 2025. It is forecasted to grow to USD 1,013.6 Million by 2034, exhibiting a CAGR of 9.12% during the period 2026-2034. This growth is driven by rising awareness of genetic disorders, increasing adoption of personalized medicine, expanding genomic research, technological advancements, government initiatives, and growing demand for prenatal and postnatal genetic screening.
Study Assumption Years
- Base Year: 2025
- Historical Year/Period: 2020-2025
- Forecast Year/Period: 2026-2034
Brazil Genetic Testing Market Key Takeaways
- Current Market Size: USD 462.1 Million in 2025
- CAGR: 9.12%
- Forecast Period: 2026-2034
- Increasing awareness of genetic disorders is backed by educational campaigns and significant contributions from governmental and non-profit organizations.
- Personalized medicine adoption is expanding, with genetic testing helping develop individualized patient therapies, particularly in oncology, cardiology, and neurology.
- Collaborations such as those between MGI Tech Co., Ltd. and Sabin Group aim to improve accessibility and quality of genetic testing in Brazil.
- Regional research such as the study by São Paulo State Cancer Institute on pancreatic cancer contributes to understanding genetic factors in Brazil.
- Growing demand for timely identification and customized treatments drives integration of genetic testing in long-term health management.
Sample Request Link: https://www.imarcgroup.com/brazil-genetic-testing-market/requestsample
Brazil Genetic Testing Market Growth Factors
Increasing awareness regarding genetic disorders and genetic testing services is one of the major factors helping in the growth of the market. According to the report, increasing awareness among people regarding genetic disorders coupled with educational initiatives and programs for hereditary diseases and genetic susceptibility testing is helping the market grow. Government and non-profit organizations are increasing awareness of the PGV. In a study from the São Paulo State Cancer Institute, PGVs were identified in 6.25% out of 192 Brazilian pancreatic ductal adenocarcinoma patients. An additional 13% of the patients had PGVs in genes typically not associated with pancreatic cancer. The demand for regular health check-ups for cancer, cardiovascular disorders, and genetic disorders is expected to improve the understanding and knowledge of the genetic contribution to various diseases, thereby propelling the market growth.
Growth of the market is also due to the increasing trend for personalized medicine. Genetic testing is used by physicians to create a personalized medicine plan for patients based on genetic data to improve treatment effectiveness while minimizing side effects. Genetic testing is widely used in cancer, cardiology, and neurology, and the development of genomic diagnostic tests has led to accurate diagnoses and more personalized treatment options. Precision health has also increased partnerships between genetics testing laboratories with pharmaceutical companies. For instance, a partnership was announced between MGI Tech Co., Ltd., and Sabin Group in Brazil to provide genomic diagnostics solutions for oncological and germline testing, expanding the access to such high-level testing and services.
The market is driven by technological investments and government initiatives. The entry of next-gen sequencing technologies into Brazil’s healthcare ecosystem, such as MGI Tech’s partnership with Dasa, promotes health diagnosis through genetic sequencing. As there are some public and private movements towards using this technology for improved disease diagnosis, such as for cancer and rare diseases, increased consumer awareness, and better access to information on genetic medicine, there has also been an increase in demand for pre- and post-natal genetic testing. These improvements built the foundation for health and genetic testing services that drive the market forward.
Brazil Genetic Testing Market Segmentation
Test Type Insights:
- Prenatal Testing
- Carrier Testing
- New Born Testing
- Predictive/Presymptomatic Testing
- Diagnostic Testing
- Others
Disease Insights:
- Cancer
- Down Syndrome
- Thalassemia
- Others
Technology Insights:
- Bio Chemical
- Molecular
- Cytogenetic
Service Provider Insights:
- Hospital Based
- Independent Laboratories
- Speciality Clinic
Testing Sample Insights:
- Blood
- Saliva
- Hair
- Others
Regional Insights:
- Southeast
- South
- Northeast
- North
- Central-West
Recent Developments & News
- On September 16, 2025: PlexBio Co., Ltd. formed a strategic partnership with Biomédica Brazil to offer molecular diagnostic products and the πCode® detection platform for cancer gene mutation testing throughout Brazil. This aims to improve cancer genetic testing access, supporting precision medicine in emerging markets.
- On September 18, 2025: MGI Tech partnered with Dasa, Latin America’s largest medical diagnostics company, to advance genetic sequencing for health diagnosis in Brazil. This alliance enhances Dasa’s ability to diagnose diseases such as cancer and rare conditions more precisely through MGI’s genomic technologies, significantly improving next-generation genomics access and personalized medicine advancement.
Key Players
- MGI Tech Co., Ltd.
- Sabin Group
- PlexBio Co., Ltd.
- Biomédica Brazil
- Dasa
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request Customization:- https://www.imarcgroup.com/request?type=report&id=29889&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
